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1. Introduction 
Seeing is believing, but the reverse, namely, disbelieving the unseen may often go against 
the spirit of scientific exploration. This is particularly true for nano-scale objects 
interacting almost invisibly with biological cells, tissues or organs. Interestingly many of 
the biological sub-cellular components (e.g. proteins, DNA)have nano-scale dimension. 
The apparently innocent (chemically inactive) and tiny particulate matter originating from 
various natural or artificial sources (e.g., pollutant) have been shown to be toxic at 
different  physiological levels. The famous saying by Jeevaka, the legendary physician of 
the Jataka tales,  that there is no herb in the world that is not a drug, however follows. 
What is toxic in some context have important therapeutic value elsewhere. Nanoparticles 
do interfere with the thrombo-static equilibrium. While this shift on one hand is a matter 
of concern, it may provide us a tool to handle or diagnose diseases in which such 
equilibrium is shifted. One of the finest models to test this dual aspect of the nano-scale 
objects is Acute Coronary Syndrome (ACS), a leading cause of death in the global 
scenario. What is known today regarding the effect of nanoscale objects may really be a 
tip of iceberg and with the advent of smarter nanoparticles one may think of more 
versatile use of nanotechnology in the management of ACS.  
2. Role of platelets in Acute Coronary Syndrome (ACS) 
ACS is a complex and multi-factorial disease (Badran et al., 2009). ACS is an umbrella like 
term which includes mainly three diseases i). ST elevated myocardial infarction (STEMI), 
ii). Non ST elevated myocardial infarction (NON STEMI), and iii) unstable angina. The 
patho-physiological event of ACS can be divided into four phases: 
a. Atherosclerotic plaque formation. 
b. Rupture of an unstable plaque. 
c. The acute ischemic event. 
d. Long term risk of recurrent coronary event. 
2.1 Platelet basic physiology 
Platelets play a pivotal in manifestation of ACS. Platelets are discoid in shape, with 
approximate number density 150,000-300,000/µl, and dimension of the order of 2000-4000 
nm.  Derived from megakaryocyte (figure 1) (Thompson, 1986) they contain mitochondria, 
peroxisomes, endoplasmic reticulum. They also contain granules and glycogen bodies. 
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Granules occur as i) dense granules (δ), ii) alpha granules (α). Dense granules mainly 
contains ATP, ADP, serotonin etc., whereas alpha granules contain fibronectin, fibrinogen, 
platelet activation factor (PAF) etc. (Marcus et al, 1966; Flaumenhaft et al, 2005). Ca++, one of 
the most important factors for platelet action, is stored in endoplasmic reticulum and 
released into the cytoplasm, during platelet activation (Nesbitt et al, 2003). Open canalicular 
system (OCS) is a channel like protrusion inside the platelet where granules release their 
contents (Escolar & White, 1991). Recently role of mRNA and mi-RNA has been shown to 
play important roles in platelet aggregation (Calverley et al, 2010; Rowley et al, 2011; 
Nagalla et al, 2011).  
 
 
Fig. 1. Precursor megakaryocyte and progenitor platelets: Represents microscopic image 
(20X) of a megakaryocyte in the bone marrow. Platelets generated from the megakaryocyte 
can be seen in 12 o’clock position of the megakaryocyte.  
When exposed to agonists, platelets become activated and this is followed by an 
aggregatory response (Patscheke, 1979). In systemic blood flow platelets remain in resting 
phase, without being activated (Marcus et al, 1991). Physiological agonists like collagen, 
thrombin, ADP, ATP etc. are not associated with the normal blood flow. Even if a trace 
amount of ADP and ATP are present, they are broken down by the phosphatase activity of 
CD39 (Marcus et al, 1997). At wound site, sub endothelial layers get ruptured. Hence Von 
Willebrand factor (vWf) and collagen get exposed causing activation of platelets (Nyman , 
1980; Tschopp et al., 1980). After the primary phase of activation and aggregation, platelet 
granules are released, this leads to enhancement of local concentration of agonists (e.g. 
granule secreted ADP, ATP, serotonin etc.). This triggers irreversible secondary phase 
platelet aggregation with fibrinogen, which is further followed by cessation of bleeding 
(Decie and Lewis 2003) (figure 2).  
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Fig. 2. Schematic diagram of platelet activation and aggregation. In the resting conditions 
platelets, maintain their discoid form and flow in circulation. Upon injury, platelets become 
exposed to sub-endothelial collagen and vWf (1) adhered on it (2). This is followed by 
activation and shape changes (3). The next phase is granules release and  secondary phase 
aggregation (4) and lastly the stable platelet plaque forms(5). 
The detailed mechanism of platelet function depends on the complex intracellular signalling 
pathways. This leads to platelet activation by simulating a series of physiological events. 
Briefly, after binding of agonists, the corresponding receptors trigger downstream signalling 
cascades and initiates Ca++ mobilisation from endoplasmic reticulum. Platelet granules 
release (┙ and ├), platelet shape change and the thromboxane A2 (TXA2) production then 
follows. The cumulative effects of these events initiate activation of fibrinogen receptor 
(GPIIbIIIa) and triggering of primary phase  aggregation. The released granules-content 
(ADP, ATP etc.) along with TXA2 activate other resting platelets resulting the secondary 
phase aggregation (Kroll & Schafer, 1989; Ashby, 1990) (figure 3). The important signalling 
molecules that help the above process through a complex interplay among different G-
protein coupled receptors, integrin receptors, second messengers, kinases, phosphatise and 
Ca++ mobilisation etc (Dorsam & Kunapuli, 2004; Wu e al., 2006,2010;  Roberts et al.,2004; 
Karniguian et al., 1990; Farndale, 2006; Spalding et al., 1998; Patscheke , 1980; Clifford et al., 
1998; Hoffman et. al. 2009).  
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Fig. 3. Schematic diagram of agonists induced platelet activation. Binding of agonists with 
corresponding receptors, triggers downstream signalling cascade, and causes mobilisation 
of intracellular Ca++. The initial Ca++ flux branches itself into three major signalling events: 
A (alpha and dense granules release), B (platelet shape change), C (TXA2 production).  The 
three signalling events cumulatively determine the activation and aggregation. The released 
chemicals (ADP,ATP etc) from granules and the TXA2, further activates other resting 
platelets and initiates the secondary phase of aggregation.    
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2.2 Platelet in ACS 
It may be contextual to focus on the pathological role of platelets in ACS. Platelet thrombosis 
plays a central role in the pathogenesis of Acute Coronary Syndrome (ACS) by the 
formation of thrombi at the site of the ruptured atherosclerotic plaque (figure 4) (Massberg  
et al., 2003; Kottke-Marchant, 2009; Lakkis et al., 2004).  
 
 
Fig. 4. Flow chart illustrating the role of  platelets in thrombus formation. 
Thus, the main therapeutic regime for the treatment of ACS is use of anti-platelet drug that 
inhibits platelet hyper aggregation (Faxon, 2011; Guha et al., 2009; Aragam & bhatt, 2011; 
Born & Patrono, 2006). Table 1 describes a list of such drugs, while their mode of action is 
illustrated in figure 5.    
In the normal platelet aggregation process, downstream signalling induces fibrinogen receptor 
activation (GpIIbIIa). GpVI is the collagen receptor. P2X1 is the receptor of ATP and acts as 
Ca++ channel. P2Y1 is high affinity ADP repector and P2Y12 is low affinity ADP receptor, 
where the former one is Gq and the later one is Gi coupled. Gz coupled alpha 2a are adrenergic 
receptors for epinephrine, where Gs coupled PGI2R are the receptors of prostaglandin I2 (PGI2) 
or prostaglandin E1 (PGE1), these being inhibitory receptors. Protease-activated receptor 1 
(PAR1), protease-activated receptor 4 (PAR4), are coupled with Gq and G13 these being the 
receptors of thrombin. Thromboxane A2 (TxA2) receptor TP is also coupled with Gq and G13. 
Released TxA2 (b in figure 5) and ADP (a in figure5 ) further act on their corresponding 
receptors. The second messengers and other signalling mediators include, (DAG) 
diacylglycerol;  (PLC┚)  phospholipase C ┚ ;  (PKC) protein kinase C; (PIP2 )  
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Mode of Action Name of the drugs 
Cyclo-oxygenase inhibitors (COX1), (1) Aspirin 
P2Y12 receptor inhibitors(2) Clopidogrel, Prasugrel, Ticlopidine 
Phosphodiestarase inhibitors(3) Cilostazole 
Glycoprotein GPIIbIIIa inhibitors(4) Abciximab, Eptifibatide, Tirofiban 
Adenosine uptake inhibitors(5) Dipyridamole 
Table 1. List of anti-platelet drugs – their mode of action and generic names. The most 
common drugs are described in the first two rows.  
 
 
Fig. 5. Target sites for anti-platelet drugs in platelet signalling pathway- different 
downstream signalling pathways are shown. The drug targets described in Table 1 are 
represented by the corresponding numbers (see text for elaboration).  
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phosphotidylinositol-4,5-biphosphate; (PLC┛) phospholipase C ┛; (PLC┚) phospholipase C ┛; 
(IP3) inositol triphosphate; (IP3R) inositol triphosphate receptor; (PP) protein 
phosphorylation; (PLA2) Phospholipase A2; (AA) arachidonic acid; AkT and Rap1B (which 
are serine /threonine kinase), (PI3K) phosphatidylinositol 3-kinase; (AC) adenylyl cyclase; 
(PKA) phosphokinase A; (cAMP) cyclic adenosine mono phosphate; (VASP) vasodialator 
stimulated phosphor protein; (P160 ROCK) a Rho activated kinase,  (MLCK) myosine light 
chain kinase, (LIM-K) LIM kinase; (PGG2) prostaglandin G2; (PGH2) prostaglandin H2; (PL) 
membrane phospholipids; (COX1) cyclooxygenase 1; (TS) thromboxane synthetase and 
(PDEIII) phosphor di-esterase III. As platelets are the key player in ACS, any extra-
physiological environmental materials that can alter platelet signalling circuit  is of great 
challenge in combating the disease. This is the context where nanotechnology can come in 
picture. 
3. Nano-interface 
Nanotechnology has the potential to interfere with basic biological mechanisms because of 
their tunable electrical, magnetic and optical properties, and small size ( Chen et al., 2005; 
Gobin et al., 2007; Fu et al., 2007). This tunability makes them potential tool in diagnostics 
(e.g. bio-imaging) therapy and a smart combination of both of these properties (Smith et al., 
2008; Peng et al., 2000; Li et al., 2003; Murry et al., 2000). 
Some of advancement of nanotechnology inspired application include improved imaging 
contrast agents by SPIONS (super-paramagnetic iron oxide nanoparticles), targeted 
delivery of drugs, molecular chaperons and agents to kill specific cancer cells (Yu et al., 
2011; Petkar et al., 2011; Patra et al., 2007). Another exclusive application involve magnetic 
induction (radio frequency) heating or laser induced heating of designer particles, with 
desirable material and shape attributes (Peterman et al., 2003; Plech et al., 2004).  The 
hyperthermic killing of tumor cells, is one of the most important examples (Rao et al., 
2010; Huff et al., 2007). The recently reported chaperon properties of nanoparticles can 
also have important biomedical potential (Singha et al., 2010). Interestingly there are only 
few report on  haematological (Elias & Tsourkas 2009; Baker, 2009; Walkey et al., 2009; 
Wickline et al., 2005) and cardiological applications (Lanza et al., 2006; Iverson et al., 2008) 
of nanotechnology.  
4. Nanotechnology in ACS and platelet contexts 
Nanotechnology is important in ACS because of several reasons. A simple application is 
imaging of plaques, conventional methods being grossly inadequate for such purpose 
(Nikolas, 2009; Wicklinea & Lanza, 2003). Secondly, the targeted delivery of therapeutic 
agents using nanoparticles to the areas of injured or dysfunctional vascular wall that 
inhibit the plaque progression is of significant importance in the ACS context (Nikolas, 
2009). 
Furthermore, nanoparticle based assay can be used for the detection of myocardial injury in 
patients with ACS (Wilson et al., 2009). In the therapeutic regime , an important use of 
nanotechnology is  to increase the amount of HDL in circulation interning  delivery of 
cholesterol to liver, thus minimizing the risk associated with ACS (Luthi et al., 2010). 
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Fig. 6. Diverse applications in nanotechnology 
In most of the above mentioned cases (diagnosis, drug delivery or treatment) the 
primary entry route of nanoparticle is through circulation where they interact directly 
with blood cells. Conversely exposure to  unwanted nanoparticles (e.g. gas phase 
exhaust from car or industry ) inhaled by human, that can penetrate the alveolar space 
and interfere with circulation may lead to cardiovascular diseases ( Yamawaki & Iwai, 
2006; Mohmmad et al., 2011; Chen et al., 2008). In both cases such interaction deserves a 
special attention.  
In case of ACS patients, if nanoparticles activate platelets then they may induce life 
threatening alarm. Till now there are a number of papers (Geys et al., 2008; Oberdörster et 
al., 2007; Deb et al., 2007,2011; Wiwanitkit et al., 2009; Radomski et al., 2005; Shrivastava et 
al., 2009; Koziara et al., 2005;  Mayer et al., 2009; Li et al., 2009; Ramtoola et al., 2010; 
McGuinnes et al., 2010; Nemmar et al., 2003; Gulati et al., 2010; Cejas et al., 2007; Wilson et 
al., 2010; Rückerl et al., 2007) about the effect of nanoparticles on platelets (Table. 2.) 
where most of the citations show that nanoparticles can induce platelet aggregation. What 
makes a nanoparticle pro-aggregarory (Geys et al., 2008; Oberdörster et al., 2007; Deb et 
al., 2007,2011; Wiwanitkit et al., 2009; Radomski et al., 2005; Mayer et al., 2009; McGuinnes 
et al., 2010; Nemmar et al., 2003; Cejas et al., 2007; Wilson et al., 2010; Rückerl et al., 2007; 
Miller et al., 2009),  inert (Li et al., 2009; Ramtoola et al., 2010; Gulati et al., 2010) or even 
anti-platelet in nature (Shrivastava et al., 2009; Koziara et al., 2005; Miller et al., 2009) is of 
great importance in development of  ACS based nano-drugs, risk assessment in ACS , and 
also in evaluating  resistance to ACS related drugs (Guha et al., 2009; Jogns et al., 2006; 
Michelson et al., 2006). 
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TYPE OF NANOMATERIALS 
EFFECT ON 
PLATELETS 
Carbon NP 
Carbon nanoparticle (C60)
Standard urban particulate matter
Multiwall carbon nanotube
Single wall carbon nanotube
Mixed carbon nanotube
Inert 
Activation 
Activation 
Activation 
Activation 
Metallic NP 
Gold nanoparticle
Iron nanoparticle
Cupper nanoparticle
Cadmium sulphide nanoparticle
Cadmium sulphide nanorod
Quantum dots
Silver nanoparticle
Activation 
Activation 
Activation 
Activation 
Activation 
Activation 
Anti-platelet effect 
Polymer NP 
and 
Bio- derived 
NP 
Short collagen related peptide
Amidine White Polystyrine Latex NP(+ve)
Aminated Polystyrine Latex NP (+ve)
Carboxylated Polystyrine Latex NP (-ve )
Unmodified Polystyrine Latex NP
PNIPAAM
PEG coated PNIPAAM
poly(D,L-lactide-co-glycolide) (PLGA)
Chitosan nanoparticles
Human and Bovine derived NP
Hydroxyapatite
E78 NPs
PEG coated E78 NPs
Activation 
Activation 
Activation 
Activation 
Inert 
Inert 
Inert 
Inert 
Inert 
Anti-platelet effect 
Anti-platelet effect 
Anti-platelet effect 
Anti-platelet effect 
Aerosol 
Ultra fine particles
Ambient Particulate Matter
Activation 
Activation 
Table 2. Nanoparticle effects on platelets – the Table enlists how the platelet response varies 
with variation in nano-material as well as the corresponding nano-surface configuration. NP 
is nanoparticle. 
5. Platelet nanoparticle interaction – A deeper insight 
A different paradigm of nanotechnology application has recently got considerable  interest. 
How thrombotic response is modulated by nanoparticles has recently become a new paradigm 
in nano-medicine. Till today, the exact mechanisms of how nano-surface exposure or uptake of 
nanoforms alter the platelet response are not known. Most of the metallic nanoparticles, 
carbon nanoparticles, aerosol and polymer nanoparticles induce platelet aggregation (Mayer et 
al., 2009; McGuinnes et al., 2011). A few nanoparticles remain inert for platelet or induce anti-
platelet effect (Li et al., 2009; Ramtoola et al., 2010; Gulati et al., 2010). Interestingly in case of 
some polymer nanoparticles, surface conjugation induces varying response to platelets 
(McGuinnes et al 2010). One needs deeper insights in induced platelet signalling to explain 
such varying response to nanoparticles with a characteristic surface property.  
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As mentioned earlier, anti-platelet drug therapy is the most important therapeutic regime 
for ACS patients. A major fall-out of the conventional therapeutic approach is the sizable 
incidence of drug resistance among ACS patients (Guha et al., 2009; Jogns et al., 2006; 
Michelson et al., 2006). There are indications that nanotechnology can help diagnosis of drug 
resistance (Deb et. al. 2011).  
Again, metallic nanoparticles can induce platelet aggregation depending on the 
physiological state of the platelets. For a given nano-drug   such response can show inter 
individual variations, and there is evidently a scope of judging the safety of such drugs 
depending on the extent of induced alteration in platelet function.  It may be important to 
note that under certain conditions nanoparticles can be hazardous to both normal 
individuals as well as ACS patients. Table 3 summarises the overall ACS risk associated 
with nanoparticles : 
 
Phenomenon Risk Factors 
< 60 nm nanoparticle. Safe in context to thrombotic risk. 
Resting platelets + nanoparticle. No thrombotic risk. 
Anti-platelet drug like clopidogrel or reo-
pro. 
No thrombotic risk. 
Rupture plaque (where vascular bed is 
open) + Nanoparticle of any size. 
High thrombotic risk. 
Some special surface modification tunable 
Table 3. Overview of thrombotic risk factors of nanoparticles.   
5.1 Excitability of the nanoparticle mediated pro-aggregatory response 
Metallic nanoparticle (made of gold, copper, iron, cadmium sulphide and quantum dots) 
induced platelet aggregation is intriguing as the profile change of such aggregation fully 
depends on the physiologic conditions of the platelets (e.g. pre-activation) (Deb et al., 2007, 
2011; Geys et al., 2008). Non-metallic carbon nano-tube or polymer based nanoparticles on 
the other hand induce platelet aggregation  without any pre-activation, their pro-
aggregatory effect depends mainly on hydrophobic collapses (Radomski et al., 2005) or 
charge-charge interaction among platelets and nanoparticles (McGuinnes et al., 2010). At 
critical concentrations of ADP or in presence of a threshold shear force, which mildly 
activates the platelets, they  become most sensitive to nano-particles (figure 7). In other 
words, the nanoparticles in such cases serve as agonists. On the other hand, when platelets 
are in resting condition  most of the metallic nano-forms seems to be inert.  
Unlike optimal size response (of nanoparticles) observed in case of cancer cells, the nano- 
response in platelets increases monotonically with decreasing size of nanoparticles (Deb et 
al., 2011). This phenomenon occurs also in case of polystyrene nanoparticles  (Mayer et al., 
2009). This size attribute is similar to entry of the nanoparticles through inhalation. Smaller 
the size of the nanoparticle, lesser in the efficiency of the clearance by alveolar macrophages, 
which in turn increases their (nanoparticle) deposition in alveolar cell leading to entry into 
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circulation (Yamawaki & Iwai, 2006). Thus, smaller nanoparticles pose a higher risk in the 
ACS scenario. 
 
 
Fig. 7. Nanoparticle Size Response.  Gold Nanoparticle induced platelet response [see Deb et. 
al. 2007,2011] is dependent on nanoparticle size, smaller particle showing aggregatory effects.  
Though the exact molecular mechanism of metallic-nanoparticle platelet interaction is yet to 
be established, systemic response like release of platelet granules (both ┙ and ├) have  been 
observed in presence of nano-particles. In presence of apyrase (scavenge ADP released from 
├ granules), or anti-platelet drug clopidogrel (block P2Y12 purinergic receptors, thus inhibit 
secondary wave of aggregation, which is the signature of granules release) nano-particle 
induced aggregation inhibited. In presence of Arg-Gly-Asp-Ser (RGDS) (a tetra-peptide, 
which binds to fibrinogen receptor GpIIbIIIa, mimicking the anti-platelet drug Reo-Pro), 
nano induced platelet aggregation is again inhibited. This reflects that nanoparticles 
induced aggregation is not due to any physico-chemical agglomerate formation. 
Consequently, metallic nano-forms are unlikely to activate platelets from patients  under 
anti-platelet drug therapy (Deb et al., 2011). Alternatively, conjugation of anti-platelet drugs 
(or combined administration of such drugs) can help to reduce the thrombotic risk of 
nanoparticle based drug formulation.   
www.intechopen.com
  
Acute Coronary Syndromes 
 
18
5.2 Platelet Response as a measure for nano-safety 
In the suspended condition, metallic nanoparticle induced platelet aggregation is highly 
dependent on the local ADP concentration. A  transition  of deaggregation to aggregation 
occurs at a threshold concentration of ADP. Interestingly, nanoparticle effect is most 
pronounced at this threshold concentration (Deb et al., 2007). This threshold nano-response 
is perhaps a manifestation of primary triggering of granules release which undergoes an 
auto-catalysis, ultimately  leading to aggregation.   
As there is a considerable variation of platelet aggregation among individuals, the threshold 
ADP concentration and extent of enhancement of aggregation induced by the nanoparticle 
have an individual specific fingerprint. The parameters thus can be used as nano-safety 
indices. Higher the threshold value and lower the nanoparticle induced aggregation, safer is 
the nano-drug (Deb et al., 2011). 
5.3 Nanoparticles and antiplatelet drugs 
Aspirin and Clopidogrel are most widely used anti-platelet drugs for ACS .In many cases dual 
antiplatelet drug (both Aspirin and Clopidogrel) therapy is used for patient safety (Born et al, 
2006, Guha et al., 2009, Faxon 2011, Aragam et al., 2011)  Despite the benefits of dual 
antiplatelet therapy, many patients still suffer from cardiovascular disease due to resistance to 
such drugs. The drug resistance also increases the risk of the recurrent occurrence of ACS 
(Guha et al., 2009; Jogns et al., 2006; Michelson et al., 2006). It is thus important to have a quick 
sensor that will assess the resistance to aspirin or clopidogrel in patients in one step and also 
assess the equivalence of the drug effects with respect to variations in geographic populations 
(which may correspond to genetic variations of patient population) and variations in effective 
drug dose among different drug manufacturers (Deb et al., US patent application, 2011). 
Interestingly among the ACS patients, one’s showing resistance to the conventional anti-
platelet drugs (e.g. aspirin or clopidogrel) respond differentially to gold nanoparticle 
(~20nm) as compared to one’s responding to it. This differential response can be used as a 
convenient classifier of  responders and non responder to antiplatelet drugs (see figure 8).  
5.4 Nano-material nano-surface and  nano-response 
Though most of the nano induced response is pro-aggregatory in nature, a few reports 
Mention inert nature of some nanoparticles (Li et al., 2009; Ramtoola et al., 2010; Gulati et al., 
2010). As most of the nano-particles induce platelet aggregation, so it can be said the 
aggregatory nature of nano surface depends on its diameter rather than its component 
material. But this conjecture is not applicable to all nano-forms. Charged surface (aminated - 
positively charged or carboxylated - negatively charged) polystyrene latex nano-forms are 
capable of inducing platelet aggregation, whereas unmodified latex beads are unable to do 
so. Interestingly, the modes of aggregation for positive and negatively charged 
nanoparticles are different. For carboxylated nanoparticle the aggregation is due to the 
upregulation of surface adhesion molecules, whereas aminated nanoparticles alter the 
platelet membrane and interact with the anionic phospholipid  (Mayer et al., 2009; 
McGuinnes et al., 2010). Though both of the charged particles are capable of inducing 
platelet aggregation, the negatively charged larger particles (larger than 60nm) are shown to 
be  less toxic in the platelet activation context (Mayer et al., 2009).The lesser toxicity of the 
such particle is probably due to less entry and charge repulsion between nano particles and 
platelets. Human cell derived nanoparticles that actually accentuate platelet granules 
www.intechopen.com
 Thrombotic Inception at Nano-Scale 
 
19 
release, inhibit platelet aggregation. This paradox is possibly due to the reduction of 
platelet-platelet interaction in presence of nanoparticle (Miller et al., 2009). Negatively 
charged Polyethylene glycol (PEG) coated nanoparticles from Microemulsion precursor 
(PEG-E78) induces platelet inhibition (Koziara et al., 2005). Importantly, in both pro-
aggregatory or antiplatelet responses , the nanoparticles are effective inducer when added in 
the pre-incubation stage. Neither the inhibition nor the aggregatory response are observed 
once the aggregation is initiated by an agonist (Koziara et al., 2005; Deb et al. 2007, 2010). 
Similar argument holds good for anti-platelet effect of silver nanoparticles prepared with a 
certain surface attributes (Shrivastava et al., 2009). Silver nanoparticles with a different 
surface conjugations again show pro-aggregatory effects (Deb et al., 2011 (in press)).  
 
 
Fig. 8. Nanosensor for Drug Resistance in ACS [89]-Using Nanoparticle effect to discriminate 
between responder and non-responder of antiplatelet drugs (e.g. aspirin and clopidogrel).  
The important question that crops up here is whether in the platelet context it is the nano-
surface conjugation or the nano-material that play the lead role. It follows that by modulating 
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the nano-surface, one can tune the thrombotic level, the desirable level depending on the 
patient status. For ACS, the desired state is a nanoform that attenuates the  aggregatory 
response, and in case of hemorrhage the situation may be complimentary in nature.  
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